ReviewBMC pediatrics2026
Dynamic changes in the corpus callosum in a case of HIVEP2-related disorder: a case report and literature review.
Review in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAutosomal dominant intellectual developmental disorder type 43 (MRD43) is a rare neurodevelopmental disorder caused by mutations in the HIVEP2 gene. Although previous cases have established core phenotypic features, detailed descriptions of neuroimaging evolution and effective epilepsy management strategies remain limited. This case presents novel findings: it identifies a previously unreported pathogenic variant, documents dynamic changes in the corpus callosum, and details a successful combination antiepileptic drug regimen, providing comprehensive insights into the natural course and clinical management of this disorder. CASE PRESENTATION: We report a 14-year-old male who presented with global developmental delay, intellectual disability, and epilepsy. An initial brain magnetic resonance imaging (MRI) suggested slight thinning of the corpus callosum (involving the genu, rostrum, and body), though a subsequent review found no abnormalities. Genetic testing identified a novel de novo pathogenic variant in the HIVEP2 gene (NM_006734.4: c.3412 C > T, p.Q1138X), confirming the diagnosis of MRD43. His seizures were effectively controlled with a combination of levetiracetam and lamotrigine, which was accompanied by improvement in his electroencephalogram findings.
conclusionsThis case expands the clinical and radiological spectrum of MRD43. The observation of evolving corpus callosum abnormalities suggests a previously underappreciated progressive neurodevelopmental component to the disorder. Furthermore, the positive response to combination antiepileptic therapy offers a practical management reference for clinicians. This report underscores the importance of longitudinal neuroimaging and tailored treatment in managing HIVEP2-related disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.